- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
CADx gets approvable letter
Another developer of computer-assisted detection systems may be close to entering the market. CADx Medical Systems of Quebec has received an FDA approvable letter for its CAD mammography system. Final approval would clear the way for the company to sell
Another developer of computer-assisted detection systems may be close to entering the market. CADx Medical Systems of Quebec has received an FDA approvable letter for its CAD mammography system. Final approval would clear the way for the company to sell its film-based Second Look product in the U.S. Only the company's combination film digitizer and image report generator would be allowed to enter the U.S. market. Software packages that the company is developing for integration with digital mammography systems from Fischer Imaging and Hologic would not be affected. CADx has been selling Second Look overseas for close to a year. About 25 systems have been installed in more than a dozen countries. List price outside the U.S. is $169,000.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.
